These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 22507773)

  • 21. Iron-chelating therapy for transfusional iron overload.
    Musallam KM; Taher AT
    N Engl J Med; 2011 Apr; 364(15):1476; author reply 1477. PubMed ID: 21488787
    [No Abstract]   [Full Text] [Related]  

  • 22. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
    Kattamis A; Kassou C; Berdousi H; Ladis V; Papassotiriou I; Kattamis C
    Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
    [No Abstract]   [Full Text] [Related]  

  • 23. Management of transfusion-dependent β-thalassemia (TDT): Expert insights and practical overview from the Middle East.
    El-Beshlawy A; Dewedar H; Hindawi S; Alkindi S; Tantawy AA; Yassin MA; Taher AT
    Blood Rev; 2024 Jan; 63():101138. PubMed ID: 37867006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Current management of thalassemia intermedia].
    Thuret I
    Transfus Clin Biol; 2014 Nov; 21(4-5):143-9. PubMed ID: 25282488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major.
    Waheed N; Ali S; Butt MA
    J Ayub Med Coll Abbottabad; 2014; 26(3):297-300. PubMed ID: 25671931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contemporary approaches to treatment of beta-thalassemia intermedia.
    Taher AT; Musallam KM; Karimi M; Cappellini MD
    Blood Rev; 2012 Apr; 26 Suppl 1():S24-7. PubMed ID: 22631038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
    Alavi S; Ebadi M; Ghazizadeh F; Arzanian MT; Shamsian B; Abdollah Gorji F
    Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
    Wu SF; Peng CT; Wu KH; Tsai CH
    Hemoglobin; 2006; 30(2):215-8. PubMed ID: 16798646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined iron chelation therapy.
    Galanello R; Agus A; Campus S; Danjou F; Giardina PJ; Grady RW
    Ann N Y Acad Sci; 2010 Aug; 1202():79-86. PubMed ID: 20712777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A decisional algorithm to start iron chelation in patients with beta thalassemia.
    Danjou F; Cabantchik ZI; Origa R; Moi P; Marcias M; Barella S; Defraia E; Dessì C; Foschini ML; Giagu N; Leoni GB; Morittu M; Galanello R
    Haematologica; 2014 Mar; 99(3):e38-40. PubMed ID: 24598857
    [No Abstract]   [Full Text] [Related]  

  • 31. Iron overload: The achilles heel of β-thalassemia.
    Vlachaki E; Venou TM
    Transfus Clin Biol; 2024 Aug; 31(3):167-173. PubMed ID: 38849068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation.
    Motta I; Bou-Fakhredin R; Taher AT; Cappellini MD
    Drugs; 2020 Jul; 80(11):1053-1063. PubMed ID: 32557398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Iron chelation therapy for patients with myelodysplastic syndrome.
    Yeh SP; Yang YS; Yao CY; Peng CT
    Hemoglobin; 2009; 33(5):339-45. PubMed ID: 19814680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New strategies in the treatment of the thalassemias.
    Schrier SL; Angelucci E
    Annu Rev Med; 2005; 56():157-71. PubMed ID: 15660507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload.
    Galanello R
    Ann N Y Acad Sci; 2005; 1054():183-5. PubMed ID: 16339664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
    Wang CH; Wu KH; Tsai FJ; Peng CT; Tsai CH
    Hemoglobin; 2006; 30(2):257-62. PubMed ID: 16798651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2* MRI assessment.
    Chirico V; Rigoli L; Lacquaniti A; Salpietro V; Piraino B; Amorini M; Salpietro C; Arrigo T
    Eur J Haematol; 2015 May; 94(5):404-12. PubMed ID: 25200112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thalassemia incidence and treatment in China with special reference to Shenzhen City and Guangdong province.
    Li CG; Li CF; Li Q; Li M
    Hemoglobin; 2009; 33(5):296-303. PubMed ID: 19814675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thalassemia Minor and Major: Current Management.
    Choudhry VP
    Indian J Pediatr; 2017 Aug; 84(8):607-611. PubMed ID: 28435994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.